drugset
drugset / Trial / NCT02642315

The Effect of Horizant (Gabapentin Enacarbil) on Augmentation

NCT02642315 ↗

Completed 10 enrolled University of Missouri-Columbia
NaSingle-groupOpen-labelTreatment

Summary

Restless Legs Syndrome (RLS) is a common neurological disorder. Augmentation is the main complication during long-term DA treatment of RLS. This study aims to examine effect of Horizant (Gabapentin Enacarbil) on Augmentation in RLS patients.

Timeline

Start
2016-01
Primary completion
2019-05-06
Completion
2019-05-06

Drugs

EvaluationDrugModalityDoseRoute
Subject gabapentin enacarbil Small molecule 600 mg Oral

Indications

restless legs syndrome